In the vast realm of molecular diagnostics, this company shines as a trailblazer in the early detection of cancers. With a primary focus on preventing colorectal cancer, the company made headlines in 2014 with the groundbreaking launch of their product - the world’s first stool DNA test for this fatal disease. As time progressed, the company expanded its product portfolio, introducing advanced screening and precision oncological tests for various types of cancer. Despite experiencing remarkable revenue growth, the company faced a formidable challenge: skyrocketing administrative expenses and acquisition costs.

Join for free to read